印度浦那，2021年5月/MRFR新闻发布/ - 市场研究未来已发表了其半煮熟的研究报告global host cell protein testing market.
Market Highlights
According to MRFR analysis, the global host cell protein testing market is expected to register a CAGR of~5.7% from 2021 to 2027.
The global host cell protein (HCP) testing market is driven by several factors, such as developments in the biopharmaceutical field and growing R&D activities. Furthermore, the technological advancements in the HCP testing products will drive the market. Rising chronic diseases such as cancer are driving more R&D efforts to find viable treatments, contributing to market growth. According to the International Agency for Research on Cancer (IARC), the global burden of cancer in 2020 reached19.3 million cases and 10 million cancer deaths. Furthermore, according to the American Cancer Society, by 2040, the global burden of cancer will reach 27.5 million cases and 16.3 million cancer deaths.
The industry players are focusing on new product development, obtaining product approvals from the regulatory bodies for more penetration in the global host cell protein testing market. For example, in June 2019, Cygnus Technologies (US) broadened its service offerings for HCP analysis with its Mass Spec Services, which will be able to detect and quantify HCPs. Furthermore, the key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in August 2019, Cygnus Technologies announced a strategic partnership with Bio-Techne (US)to quantify Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple Ella immunoassay platform. Furthermore, in November 2020, Thermo Fisher Scientific (US) had collaborated with Northeastern University (US) to enhance its analytical capabilities and innovate in areas like monoclonal antibodies, gene, and cell therapies, where HCP testing is required
Access full report @//www.bjtldsoft.com/reports/host-cell-protein-testing-market-10651
区域分析
North America is likely to dominate the host cell protein testing market, owing to increasing investments in R&D, the presence of key companies, and developed healthcare infrastructure in the region. For instance, in 2020, the National Institutes of Health (NIH) received a funding of USD 42 billion, which has increased by 7% compared to 2019.
由于政府的支持和研发投资的增长，欧洲可能会在宿主细胞蛋白测试市场中占有很大的份额。预计市场参与者将推出新产品的新产品将进一步蓬勃发展欧洲的市场增长。例如，2019年9月，AMSBIO LLC（英国）推出了新的HCP检测套件，专门在药物开发过程的任何阶段检测HCP。
Asia-Pacific is projected to be the fastest-growing regional market during the forecast period due tothe high prevalence of chronic diseases like cancer and emerging economies. For instance, according to the World Cancer Research Fund (WCRF), in 2018, Australia had the highest cancer rate for both sexes at 468.0 per 100,000 individuals, which is boosting R&D efforts to find new viable drugs driving the HCP testing market.
Furthermore, the growth of the market in the Rest of the World is attributed to improving healthcare facilities and supportive government regulations to bring more advanced technologies into the region.
分割
全球宿主细胞蛋白测试市场已分为类型和最终用户。
By type, the market has been segmented into PCR-based assays, ELISA-based assays, and others. The ELISA-based assays segment is expected to hold the largest share of the market in 2020 as it is considered the gold standard for HCP testing.
Based on end users, the market has been segmented into Contract Research Organizations (CROs), biopharmaceutical companies, and others. The biopharmaceutical companies segment held the largest segment share in 2020because of the extensive R&D efforts and company funding to develop new therapeutics and utilization of HCP testing in the process.
关键人物;主力;重要一员
一些关键市场参与者Areenzo Life Sciences，Inc。（美国），Cygnus Technologies Inc.（美国），Biogenes GmbH（德国），Cytiva（US），Cisbio Bioassays（法国），分子设备（美国），Thermo Fisher Scientific Scientific Scientific Scientific Scientific Scientific Scientific Scientific（美国），查尔斯河（美国），Bio-Rad Laboratories（美国）和Fortebio（Pall）（美国）